MarketWatch

Structure Therapeutics details positive trial data for a weight-loss pill, and the stock rockets

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...
Morningstar

Structure details positive trial data for a weight-loss pill, and the stock rockets

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...
BioSpace

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
C&EN

Linking Structure and Topology in Single-Chain Nanoparticles Using Simulations and Scattering Data

Article subjects are automatically applied from the ACS Subject Taxonomy and describe the scientific concepts and themes of the article. In a recent study, the folding of individual 24 SCNPs for a ...